Press release
Herceptin Market Anticipated To Witness Robust Growth, Surpassing 9.59 Billion By 2029
Herceptin Market Size
What Is the Current Herceptin Market Size and Its Estimated Growth Rate?
In the past few years, the herceptin market has seen substantial growth. The market, which was valued at $7.10 billion in 2024, is predicted to rise to $7.55 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 6.4%. This significant growth during the historical period is due to factors such as regulatory approvals, an increase in breast cancer cases, advancements in monoclonal antibody technology, impressive results from clinical trials, and the surge in healare spending.
The herceptin market is predicted to witness robust expansion in the foroming years, escalating to a value of $9.59 billion in 2029 with a compound annual growth rate (CAGR) of 6.1%. The growth in the predicted timeframe is ascribed to the proliferation of biosimilars, the rising practice of targeted treatments, increased availability of healare in growing markets, continuous oncology research and development, and an increased incidence of HER2-positive cancers. Key trends during the prediction timeframe include the creation of antibody-drug conjugates, advancements in biosimilar developments, the use of artificial intelligence in drug discovery, personalized medicinal tactics, and enhancements in drug delivery systems.
Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/customise?id=24236&type=smp
How Are Emerging Segments Shaping the Herceptin Market Landscape?
The herceptin market covered in this report is segmented -
1) By Product: Biologic, Biosimilar
2) By Application: Breast Cancer, Gastric Cancer
3) By Payer: Commercial And Private, Public
4) By Distribution Channel: Hospital Pharmacy, Specialty Pharmacy
Subsegments:
1) By Biologic: Intravenous (IV) Biologics, Subcutaneous (SC) Biologic
2) By Biosimilar: Intravenous (IV) Biosimilars, Subcutaneous (SC) Biosimilars
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24236&type=smp
Which Growth Factors Are Influencing Herceptin Market Expansion?
The escalation in breast cancer cases is predicted to drive the herceptin market's expansion. Breast cancer is a form of cancer originating in the breast cells, typically commencing in the milk ducts or lobules, encompassing invasive ductal carcinoma (IDC), invasive lobular carcinoma (ILC), and HER2-positive breast cancer. The surge in breast cancer is attributed to alterations in lifestyle, including a rise in alcohol consumption, poor nutrition, and insufficient physical activity, all contributing to an elevated risk. As the diagnosis of breast cancer, specifically HER2-positive cases, continues to grow, so does the need for effective targeted treatments like herceptin. For example, the American Cancer Society, a US-based cancer organization, estimated in January 2025 that around 319,750 new cases of breast cancer would be reported in 2025, projecting approximately 42,680 fatalities from the disease. Therefore, the overall rise in breast cancer incidence fuels the herceptin market's growth.
Who Are the Dominant Players Across Different Herceptin Market Segments?
Major companies operating in the herceptin market are Pfizer Inc., Roche Holding AG, Merck & Co Inc., GlaxoSmithKline plc, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd, Boehringer Ingelheim GmbH, Genentech Inc., Dr. Reddy's Laboratories, Celltrion Healare, Mundipharma, Biocon Limited, Bio-Techne Corporation, Samsung Bioepis Co Ltd, AryoGen Pharmed, InvivoGen, Abnova Corporation, Shanghai Henlius Biotech Inc., Prestige Biopharma Pte Ltd.
What Trends Are Driving Growth in The Herceptin Market?
Key businesses in the Herceptin market are introducing cutting-edge treatment alternatives like pioneering biosimilar products, aimed at increasing patient availability and enhancing therapeutic results for HER2-positive cancers. These innovative biosimilar products, which are highly similar variations of approved organic drugs, are produced through advanced biotechnology to ensure similar safety, efficacy, and quality standards. For example, in April 2024, Accord BioPharma Inc., a pharmaceutical firm based in the US, obtained an approval from the U.S. Food and Drug Administration for HERCESSI (trastuzumab-strf), a biosimilar to Herceptin (trastuzumab). This product is designed for the treatment of cancers that ovpress HER2 in breast and gastric cells. Biosimilars like HERCESSI exhibit a similar level of efficacy and safety as the biologics they are equivalent to, potentially offering a more economical treatment approach.
Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/herceptin-global-market-report
Which Geographic Regions Are Expected to Dominate the Herceptin Market in the Coming Years?
North America was the largest region in the herceptin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the herceptin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Herceptin Market?
2. What is the CAGR expected in the Herceptin Market?
3. What Are the Key Innovations Transforming the Herceptin Industry?
4. Which Region Is Leading the Herceptin Market?
Why This Report Matters:
Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.
Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.
Efficient Research: Quickly identify market growth, leading players, and major segments.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Herceptin Market Anticipated To Witness Robust Growth, Surpassing 9.59 Billion By 2029 here
News-ID: 4060773 • Views: …
More Releases from The Business Research Company
Segment Evaluation and Major Growth Areas in the Personalized Testing and Supple …
The personalized testing and supplements sector is gaining remarkable traction, driven by advancements in technology and a rising consumer focus on tailored health solutions. As more individuals seek customized wellness options, this market is set to experience substantial expansion in the coming years. Here's an in-depth look at its current valuation, key players, significant trends, and the main market segments shaping its future.
Market Valuation and Expansion Forecast for Personalized Testing…
Top Players and Market Competition in the Skin Microbiome Industry
The skin microbiome market is emerging as a significant area of interest due to growing awareness about the critical role of skin health and innovative skincare technologies. As research advances and consumer preferences shift towards more natural and science-backed products, this market is set to undergo substantial growth. Let's explore the current market size, key players, driving factors, and upcoming trends shaping the skin microbiome industry.
Projected Expansion in the Skin…
Key Strategic Developments and Emerging Changes Shaping the Upadacitinib Market …
The upadacitinib market is poised for significant expansion over the coming years, driven by advances in treatment options and increasing awareness of autoimmune diseases. This report delves into the market's current size, key drivers, major players, and the emerging trends shaping its future trajectory.
Steady Growth Expected in Upadacitinib Market Size Through 2029
The market for upadacitinib is projected to reach $2.54 billion by 2029, growing at a robust compound annual…
Analysis of Key Market Segments Driving the Alzheimer's Disease Diagnostic Marke …
The Alzheimer's disease diagnostic sector is rapidly evolving as advancements in technology and healthcare infrastructure open new possibilities for early detection and personalized treatment. With rising awareness and innovative approaches, this market is poised for significant growth in the coming years. Let's explore the current market size, key drivers, leading companies, and emerging trends that are shaping this critical healthcare field.
Projected Market Size and Growth Trends in Alzheimer's Disease Diagnostics…
More Releases for Herceptin
Herceptin Biosimilars Market: An Overview
Herceptin (trastuzumab) is a widely used monoclonal antibody that has been pivotal in the treatment of HER2-positive breast cancer. The introduction of biosimilars for Herceptin has revolutionized the pharmaceutical landscape, offering a cost-effective alternative to the original biologic. Biosimilars are highly similar to their reference products in terms of safety, efficacy, and quality, but they are more affordable. As healthcare costs continue to rise globally, biosimilars like Herceptin are becoming…
Herceptin Biosimilar Market Accelerates 23.2% CAGR Forecast (2022-2030)
The global Herceptin biosimilar market has demonstrated significant growth in recent years, and this trend is expected to continue over the forecast period. Valued at USD 1,795 million in 2021, the market is projected to reach USD 11,287 million by 2030, reflecting a compound annual growth rate (CAGR) of 23.2% from 2022 to 2030. This robust growth is driven by several factors, including the rising prevalence of gastric and breast…
Herceptin Biosimilar Market Size, Share | Growth - 2030
Exclusive Report by Ameco Research: Herceptin Biosimilar Market Size Projected to Reach USD 11,280 Million by 2030, Growing at 23% CAGR
Ameco Research is proud to announce the launch of its latest market research report, Herceptin Biosimilar Market. This comprehensive report provides in-depth analysis and insights into the current market trends and future projections in the Industry/Market Segment. Ameco Research has been at the forefront of providing quality market research…
Herceptin Biosimilar Market | Industry Trends and Forecast 2022-2030
Acumen Research and Consulting has announced the addition of the "Herceptin Biosimilar Market" report to their offering.
The Herceptin Biosimilar Market Report 2030 is an in depth study analyzing the current state of the Herceptin Biosimilar Market. It provides brief overview of the market focusing on definitions, market segmentation, end-use applications and industry chain analysis. The study on Herceptin Biosimilar Market provides analysis of global market covering the industry trends, recent…
Herceptin Biosimilar Market to Discern Steadfast Expansion During 2029
Global Herceptin Biosimilar Market: Overview
Growing number of people living with gastric cancers and metastatic (spread) breast cancer is expected to drive demand opportunities for enterprises working in the global herceptin biosimilar market. Herceptin refers to a monoclonal antibody mainly utilized in the treatment of critical cancers like gastric cancers and metastatic (spread) breast cancer.
An upcoming research report on the global herceptin biosimilar market provides a complete analysis of this market.…
United States Herceptin Biosimilar Market 2017
In this report, the United States Herceptin Biosimilar Market 2017 is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.
Geographically, this report splits the United States market into seven regions:
The West
Southwest
The Middle Atlantic
New England
The South
The Midwest
with sales (volume), revenue (value), market share and growth rate of Herceptin Biosimilar in…
